Compare Sana Biotechnology Inc (SANA) vs Ulta Beauty Inc (ULTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Ulta Beauty Inc — how do they compare? Sana Biotechnology Inc trades at $3.79 (market cap $1.13B), while Ulta Beauty Inc trades at $531.85 (market cap $23.27B). The key difference: Ulta Beauty Inc is far larger — about 20.6× Sana Biotechnology Inc's market cap. Which is the better fit depends on your goals.
| SANA | ULTA | |
|---|---|---|
Market Cap | $1.13B | $23.27B |
Sector | Health | Consumer Cyclical |
52-Week High | $5.92 | $706.82 |
52-Week Low | $2.68 | $450.75 |
Enterprise Value | $1.05B | $25.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
ULTA stock trades at $532.14, down 3.01% today, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported Q1 2026 EPS of $7.74, beating expectations, and maintains strong profitability with a 39.33% gross margin and 47.45% ROE. Recent news highlights Ulta's omnichannel growth strategy and the end of its Target partnership, viewed as a potential revenue opportunity by analysts.
Outlook is positive with a consensus price target of $618.29, representing 16% upside, supported by 56.53% analyst buy ratings. Risks include margin compression, with net income margin projected to drop to 9.35% in 2026, and volatile cash flows, as net cash flow turned negative in 2025. Investors should weigh strong fundamentals against competitive and execution risks in the retail sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Ulta Beauty Inc
With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →
